ProShare Advisors’s RxSight RXST Stock Holding History

ProShare Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,984	Closed	-$202K	–	2170
2025 Q1	$202K	Sell	7,984 -2,245	-22%	-$66.7K	﹤0.01%	1682
2024 Q4	$352K	Buy	10,229 +3,447	+51%	+$155K	﹤0.01%	1511
2024 Q3	$335K	Buy	6,782 +2,974	+78%	+$152K	﹤0.01%	1393
2024 Q2	$229K	Sell	3,808 -1,300	-25%	-$74.3K	﹤0.01%	1460
2024 Q1	$263K	Buy	+5,108	New	+$251K	﹤0.01%	1514

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's RXST Position: Q2 2025 in Review

ProShare Advisors sold out of RxSight (RXST) in Q2 2025, closing a stake of 7,984 shares — an estimated $202K sold.

ProShare Advisors first reported a position in RXST in Q1 2024 and held it in 5 quarters. The position peaked at $352K in Q4 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

ProShare Advisors reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
ProShare Advisors sold 7,984 RxSight shares in Q2 2025, an estimated $202K.
ProShare Advisors first reported a position in RxSight in Q1 2024 and held it in 5 quarters.
ProShare Advisors's RxSight position peaked at $352K in Q4 2024.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.